The Betel Nut Intervention Trial (BENIT)-A Randomized Clinical Trial for Areca Nut and Betel Quid Cessation: Primary Outcomes.
Betel Nut Intervention Trial
areca nut
betel quid
cessation
clinical trial
oral cancer
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
21 08 2023
21 08 2023
Historique:
received:
19
06
2023
revised:
01
08
2023
accepted:
16
08
2023
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
epublish
Résumé
Areca nut and betel quid (ANBQ) chewing is a widespread carcinogenic habit. The BENIT (ClinicalTrials-NCT02942745) is the first known randomized trial designed for ANBQ chewers. We compared the intensive behavioral treatment intervention condition (IC) with the control condition (CC) in the BENIT and included a 5-stage early stopping rule. We report the primary analysis at stage 3. English-literate adults in Guam and Saipan who self-identified as ANBQ chewers with tobacco were enrolled between August 2016 and August 2020. IC participants ( Cessation rates were 38.6% (IC) and 9.1% (CC). Proportional hazards regression revealed a Robust self-reported intervention effects at day 22 suggest that intensive cessation programs such as BENIT should be further developed and implemented on a larger scale.
Sections du résumé
BACKGROUND
Areca nut and betel quid (ANBQ) chewing is a widespread carcinogenic habit. The BENIT (ClinicalTrials-NCT02942745) is the first known randomized trial designed for ANBQ chewers.
METHODS
We compared the intensive behavioral treatment intervention condition (IC) with the control condition (CC) in the BENIT and included a 5-stage early stopping rule. We report the primary analysis at stage 3. English-literate adults in Guam and Saipan who self-identified as ANBQ chewers with tobacco were enrolled between August 2016 and August 2020. IC participants (
RESULTS
Cessation rates were 38.6% (IC) and 9.1% (CC). Proportional hazards regression revealed a
CONCLUSIONS
Robust self-reported intervention effects at day 22 suggest that intensive cessation programs such as BENIT should be further developed and implemented on a larger scale.
Identifiants
pubmed: 37623205
pii: ijerph20166622
doi: 10.3390/ijerph20166622
pmc: PMC10454381
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02942745']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : U54 CA143728
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA071789
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA143727
Pays : United States
Références
IARC Monogr Eval Carcinog Risks Hum. 2004;85:1-334
pubmed: 15635762
Addiction. 2015 Sep;110(9):1533
pubmed: 26177682
Hawaii J Public Health. 2011 Mar;3(1):19-29
pubmed: 25678943
Contemp Clin Trials Commun. 2020 Feb 21;17:100544
pubmed: 32154430
Lancet Oncol. 2017 Dec;18(12):e767-e775
pubmed: 29208442
Addict Biol. 2002 Jan;7(1):77-83
pubmed: 11900626
Drug Test Anal. 2023 Jan;15(1):58-65
pubmed: 36057968
PLoS One. 2014 Nov 20;9(11):e113385
pubmed: 25411778
Hawaii J Med Public Health. 2013 May;72(5 Suppl 1):19-29
pubmed: 23900536
Oral Health Dent Manag. 2014 Jun;13(2):512-8
pubmed: 24984674
BMC Oral Health. 2014 Dec 11;14:151
pubmed: 25495475
Community Dent Oral Epidemiol. 2019 Feb;47(1):58-64
pubmed: 30238494
Drug Alcohol Depend. 2012 Feb 1;121(1-2):18-22
pubmed: 21955360
Epidemiol Psychiatr Sci. 2020 May 06;29:e125
pubmed: 32370818
PLoS One. 2018 Jul 17;13(7):e0199503
pubmed: 30016322
Pac Asia Inq. 2015 Fall;6(1):144-150
pubmed: 27057560
Cancer Epidemiol. 2017 Oct;50(Pt B):241-246
pubmed: 29120831